The dual-listing is a liquidity-enhancing move but does not change fundamentals or raise capital. Monitor for increased trading volumes and potential index inclusion in Israeli benchmarks, but no immediate catalyst for the stock price on Nasdaq. The company remains pre-commercialization with no approved product, so focus should remain on clinical trial milestones and regulatory progress.
Drug in focus
DRTS drug pipeline →Alpha DaRT
▲ Bullish Named in this 6-K- Impact
- Phase
- Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
- Time to market
- The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
- Next catalyst
- None dated
What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 10 $13.60entry
- T+1 · 3mo ago +4.93%α +5.25% · $14.27
- T+5 · 3mo ago +4.04%α +4.09% · $14.15
- T+20 · 2mo ago +9.12%α +10.03% · $14.84
- T+60 · 14d ago −0.44%α +1.98% · $13.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau Medical announced its intention to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE) while maintaining its Nasdaq listing. The company registered all outstanding shares (92,478,154) plus potential future issuances from warrants, options, RSUs, and employee plans for TASE trading. This listing broadens the shareholder base and provides Israeli investors access in local currency and hours, but does not involve raising new capital or changing the Nasdaq status.
Key Facts
- Alpha Tau intends to dual-list on Tel Aviv Stock Exchange (TASE) alongside existing Nasdaq listing.
- Registered shares include 92,478,154 outstanding ordinary shares; up to 36,733,096 shares underlying existing convertible securities (warrants, options, RSUs); up to 12,889,753 from authorized but unissued options; and up to 4,257,358 from the employee share purchase plan.
- No new capital raising or change in Nasdaq listing status involved.
- Shares will trade on TASE under symbol DRTS (English) and a Hebrew symbol.
- Alpha DaRT treatment is not yet approved for commercial use outside clinical trials.
Financial Impact
No financial figures disclosed; dual-listing does not involve new capital raise or immediate dilution.
Risk Factors
- Dual-listing does not address the lack of approved commercial product or potential clinical trial setbacks.
- Potential for increased administrative costs and regulatory compliance burden from operating on two exchanges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-086947 |
| Document: ea030130901ex99-1.htm | 0001213900-26-086947 |
| Document: 0001213900-26-086947-index-headers.html | 0001213900-26-086947 |
| Document: 0001213900-26-086947-index.html | 0001213900-26-086947 |
| Document: 0001213900-26-086947.txt | 0001213900-26-086947 |
Track record
25 reports on DRTS
9 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers